77 results about "Hcv ns3 protease" patented technology

Compounds of formula (I):

wherein R¹ is hydroxyl or sulfonamide derivative; R² is t-butyl or —CH₂—C(CH₃)₃ or —CH₂-cyclopentyl; R³ is t-butyl or cyclohexyl and R⁴ is cyclobutyl, cyclopentyl or cyclohexyl; or a pharmaceutically acceptable salt thereof, are described as useful as inhibitor of the HCV NS3 protease.

Compounds of formula I:

wherein D, R⁴, R³, L⁰, L¹, L², R² and R^c are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

Compounds of formula (I):

wherein R¹, R², X, R³, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.

Compounds of formula (I):

wherein B, X, R³, R²¹, R²², R¹ and R^c are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.

Compounds of formula (I):

wherein R¹ is (C_1-8)alkyl, (C_3-7)cycloalkyl, {(C_1-6)alkyl-(C_3-7)cycloalkyl} or Het, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C_1-6)alkyl, amido, amino or phenyl, or R¹ is C₆ or C₁₀ aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C_1-6)alkyl, O—(C_1-6)alkyl, amido, amino or phenyl; or a pharmaceutically acceptable salt thereof, useful as an inhibitor of the HCV NS3 protease.

Compounds of formula (I):

wherein R¹, R², R³, R⁴, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Novel chromogenic, fluorogenic and fluorescence polarization substrates which are useful in HCV NS3 protease and inhibitor assays.

The present invention relates to compounds that are useful as protease inhibitors, particularly as serine protease inhibitors, and more particularly as hepatitis C NS3 protease inhibitors. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HCV NS3 protease activity and consequently, may be advantageously used as therapeutic agents against the hepatitis C virus and other viruses that are dependent upon a serine protease for proliferation. This invention also relates to methods for inhibiting the activity of proteases, including hepatitis C virus NS3 protease and other serine proteases, using the compounds of this invention and related compounds.

Compounds of formula I:

wherein R¹ is hydroxy or NHSO₂R^1A wherein R^1A is (C_1-8)alkyl, (C_3-7)cycloalkyl or {(C_1-6)alkyl-(C_3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C_1-6)alkyl, amido, amino or phenyl, or R^1A is C₆ or C₁₀ aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C_1-6)alkyl, O(C_1-6)alkyl, amido, amino or phenyl; R² is (C_5-6)cycloalkyl and R³ is cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

The invention relates to compounds of formula (I) wherein R′, R², R³, R⁴, R⁵, R⁶, Y, n and m are as defined (herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

The present invention relates to lactams of Formula (I):

or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

Compounds of formula I:

wherein R¹, R², R^2a, R³, R⁴ and R⁵ are defined herein, are useful as inhibitors of the HCV NS3 protease.